104
Participants
Start Date
August 31, 2012
Primary Completion Date
May 31, 2014
Study Completion Date
May 31, 2014
Group A (Zeffix, Sebivo, Hepsera)
Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
Group B (Baraclude, Viread)
Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Seoul St. Mary's Hospital
OTHER
The Catholic University of Korea
OTHER
Soonchunhyang University Hospital
OTHER
Pusan National University Hospital
OTHER
Kyungpook National University Hospital
OTHER
Hallym University Medical Center
OTHER
Chonbuk National University Hospital
OTHER
Yonsei University
OTHER